In the present study, we observed that the combination therapy with a selective SGLT2 inhibitor, canagliflozin, and an insulin sensitizer, pioglitazone, further improved glycemic control in the KK-Ay mice with established diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.